Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03804840 · ClinicalTrials.gov registry record · Early Phase 1
Developing a Mobile Method to Measure THC-induced Impairment
A Early Phase 1 study of Measuring THC-induced Cognitive Impairment Using a Mobile Application, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT03804840 is a Early Phase 1 study of Measuring THC-induced Cognitive Impairment Using a Mobile Application that has completed, run by University of Chicago. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03804840, a Early Phase 1 study of Measuring THC-induced Cognitive Impairment Using a Mobile Application, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
Marijuana use, for both recreational and therapeutic purposes, is becoming increasingly common as states remove restrictions on use. The increased use raises new concern about the safety of this drug, including its ability to impair basic cognitive and psychomotor tasks, and whether the users are aware of their impairment. We propose to design a simple performance test that users can use in the field, using a cell phone, to assess their level of impairment relative to their own drug-free state. In this preliminary study, we will compare participants' simple task performance after a known dose of delta-9-tetrahydrocannabinol (THC), or placebo, administered under double-blind conditions. In our app the participants will be asked to gauge their own perceived level of impairment (as determined by self-ratings and judgments of impairment) as well as their actual impairment (as gauged by the app), providing important feedback and training about their ability to detect impairment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dronabinol
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03804840
The ClinicalTrials.gov registry entry for NCT03804840 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Measuring THC-induced Cognitive Impairment Using a Mobile Application appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03804840 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03804840 about?
NCT03804840 is a clinical study titled "Developing a Mobile Method to Measure THC-induced Impairment". Marijuana use, for both recreational and therapeutic purposes, is becoming increasingly common as states remove restrictions on use. The increased use raises new concern about the safety of this drug, including its ability to impair basic cognitive and psychomotor tasks, and whether the users are aw...
What is the current status of trial NCT03804840?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2017-03-01. Estimated completion is 2018-12-01.
What conditions does trial NCT03804840 study?
This clinical trial studies the following conditions: Measuring THC-induced Cognitive Impairment Using a Mobile Application.
What interventions are being tested in trial NCT03804840?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG).
Who is sponsoring clinical trial NCT03804840?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03804840 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.